DE102011118022B4 - Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung - Google Patents

Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung Download PDF

Info

Publication number
DE102011118022B4
DE102011118022B4 DE102011118022.6A DE102011118022A DE102011118022B4 DE 102011118022 B4 DE102011118022 B4 DE 102011118022B4 DE 102011118022 A DE102011118022 A DE 102011118022A DE 102011118022 B4 DE102011118022 B4 DE 102011118022B4
Authority
DE
Germany
Prior art keywords
antibody
seq
psca
antibodies
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102011118022.6A
Other languages
German (de)
English (en)
Other versions
DE102011118022A1 (de
Inventor
Michael Bachmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avencell Europe GmbH
Original Assignee
Gemoab Monoclonals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102011118022.6A priority Critical patent/DE102011118022B4/de
Application filed by Gemoab Monoclonals GmbH filed Critical Gemoab Monoclonals GmbH
Priority to LTEP12729996.4T priority patent/LT2726507T/lt
Priority to EP12729996.4A priority patent/EP2726507B1/de
Priority to US14/129,933 priority patent/US9200078B2/en
Priority to RS20190218A priority patent/RS58448B1/sr
Priority to JP2014517736A priority patent/JP2014528696A/ja
Priority to HRP20190289TT priority patent/HRP20190289T1/hr
Priority to SM20190085T priority patent/SMT201900085T1/it
Priority to SI201231523T priority patent/SI2726507T1/sl
Priority to DK12729996.4T priority patent/DK2726507T3/en
Priority to PCT/EP2012/062716 priority patent/WO2013001065A1/de
Priority to TR2019/01991T priority patent/TR201901991T4/tr
Priority to ES12729996T priority patent/ES2711978T3/es
Priority to HUE12729996A priority patent/HUE042008T2/hu
Priority to AU2012277784A priority patent/AU2012277784B2/en
Priority to EP18207370.0A priority patent/EP3505536B1/de
Priority to PT12729996T priority patent/PT2726507T/pt
Priority to PL12729996T priority patent/PL2726507T3/pl
Priority to ES18207370T priority patent/ES2989975T3/es
Publication of DE102011118022A1 publication Critical patent/DE102011118022A1/de
Priority to JP2017002983A priority patent/JP6549622B2/ja
Application granted granted Critical
Publication of DE102011118022B4 publication Critical patent/DE102011118022B4/de
Priority to CY20191100176T priority patent/CY1121249T1/el
Priority to JP2019117977A priority patent/JP6886491B2/ja
Priority to JP2021081553A priority patent/JP7341185B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE102011118022.6A 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung Expired - Fee Related DE102011118022B4 (de)

Priority Applications (23)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
HUE12729996A HUE042008T2 (hu) 2011-06-30 2012-06-29 Prosztataspecifikus õssejt antigén elleni antitestek és alkalmazásuk
US14/129,933 US9200078B2 (en) 2011-06-30 2012-06-29 Antibodies against prostate-specific stem cell antigen and use thereof
RS20190218A RS58448B1 (sr) 2011-06-30 2012-06-29 Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba
JP2014517736A JP2014528696A (ja) 2011-06-30 2012-06-29 前立腺特異幹細胞抗原に対する抗体およびその使用
HRP20190289TT HRP20190289T1 (hr) 2011-06-30 2012-06-29 Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba
SM20190085T SMT201900085T1 (it) 2011-06-30 2012-06-29 Anticorpi contro l'antigene delle cellule staminali prostatiche e suo uso
SI201231523T SI2726507T1 (sl) 2011-06-30 2012-06-29 Protitelesa proti antigenu prostatno specifičnih matičnih celic in njihova uporaba
DK12729996.4T DK2726507T3 (en) 2011-06-30 2012-06-29 ANTIBODY AGAINST THE PROSTATE-SPECIFIC STEM CELL ANTIGEN AND ITS USE
EP12729996.4A EP2726507B1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
TR2019/01991T TR201901991T4 (tr) 2011-06-30 2012-06-29 Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı.
EP18207370.0A EP3505536B1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
LTEP12729996.4T LT2726507T (lt) 2011-06-30 2012-06-29 Antikūnai, atpažįstantys prostatai specifinį kamieninių ląstelių antigeną, ir jų panaudojimas
AU2012277784A AU2012277784B2 (en) 2011-06-30 2012-06-29 Antibodies against prostate-specific stem cell antigen and use thereof
ES12729996T ES2711978T3 (es) 2011-06-30 2012-06-29 Anticuerpos contra el antígeno de células madre específico de la próstata y su uso
PT12729996T PT2726507T (pt) 2011-06-30 2012-06-29 Anticorpos contra antigéneos celulares especificos da próstata e uso dos mesmos
PL12729996T PL2726507T3 (pl) 2011-06-30 2012-06-29 Przeciwciała przeciwko antygenowi komórek macierzystych swoistemu dla gruczołu krokowego i ich zastosowanie
ES18207370T ES2989975T3 (es) 2011-06-30 2012-06-29 Anticuerpos contra el antígeno de células madre específico de la próstata y su uso
PCT/EP2012/062716 WO2013001065A1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
JP2017002983A JP6549622B2 (ja) 2011-06-30 2017-01-12 前立腺特異幹細胞抗原に対する抗体およびその使用
CY20191100176T CY1121249T1 (el) 2011-06-30 2019-02-11 Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου
JP2019117977A JP6886491B2 (ja) 2011-06-30 2019-06-26 前立腺特異幹細胞抗原に対する抗体およびその使用
JP2021081553A JP7341185B2 (ja) 2011-06-30 2021-05-13 前立腺特異幹細胞抗原に対する抗体およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Publications (2)

Publication Number Publication Date
DE102011118022A1 DE102011118022A1 (de) 2013-01-03
DE102011118022B4 true DE102011118022B4 (de) 2018-01-18

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102011118022.6A Expired - Fee Related DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Country Status (18)

Country Link
US (1) US9200078B2 (cg-RX-API-DMAC7.html)
EP (2) EP3505536B1 (cg-RX-API-DMAC7.html)
JP (4) JP2014528696A (cg-RX-API-DMAC7.html)
AU (1) AU2012277784B2 (cg-RX-API-DMAC7.html)
CY (1) CY1121249T1 (cg-RX-API-DMAC7.html)
DE (1) DE102011118022B4 (cg-RX-API-DMAC7.html)
DK (1) DK2726507T3 (cg-RX-API-DMAC7.html)
ES (2) ES2989975T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190289T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042008T2 (cg-RX-API-DMAC7.html)
LT (1) LT2726507T (cg-RX-API-DMAC7.html)
PL (1) PL2726507T3 (cg-RX-API-DMAC7.html)
PT (1) PT2726507T (cg-RX-API-DMAC7.html)
RS (1) RS58448B1 (cg-RX-API-DMAC7.html)
SI (1) SI2726507T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900085T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901991T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013001065A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
AU2021276327A1 (en) * 2020-05-19 2022-12-01 City Of Hope Engineered anti-prostate stem cell antigen fusion proteins and uses thereof
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
CN121673412A (zh) * 2024-09-12 2026-03-17 上海医药工业研究院有限公司 一种靶向psca的纳米抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032949A2 (en) * 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4404381B2 (ja) * 1997-03-10 2010-01-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Psca:前立腺幹細胞抗原
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
KR100490077B1 (ko) * 1999-10-29 2005-05-17 제넨테크, 인크. 항-전립선 줄기세포 항원 (psca) 항체 조성물 및 그의사용 방법
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
RU2381234C2 (ru) * 2004-05-28 2010-02-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками psca
KR101837053B1 (ko) * 2008-10-01 2018-03-12 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 PSCAxCD3, CD19xCD3, c-METxCD3, 엔도시알린xCD3, EpCAMxCD3, IGF-1RxCD3 또는 FAPαxCD3 이중특이적 단일쇄 항체
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032949A2 (en) * 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Feldmann, A., Stamova, S., Bippes, C.C. et al., The Prostate, 71: 998-1011; 2011. *

Also Published As

Publication number Publication date
HUE042008T2 (hu) 2019-06-28
DK2726507T3 (en) 2019-03-11
HRP20190289T1 (hr) 2019-05-03
TR201901991T4 (tr) 2019-03-21
LT2726507T (lt) 2019-04-10
SI2726507T1 (sl) 2019-05-31
JP2017104113A (ja) 2017-06-15
JP2014528696A (ja) 2014-10-30
RS58448B1 (sr) 2019-04-30
EP2726507B1 (de) 2018-11-21
WO2013001065A1 (de) 2013-01-03
ES2989975T3 (es) 2024-11-28
JP2019193652A (ja) 2019-11-07
JP6549622B2 (ja) 2019-07-24
JP7341185B2 (ja) 2023-09-08
PL2726507T3 (pl) 2019-06-28
CY1121249T1 (el) 2020-05-29
AU2012277784B2 (en) 2015-08-20
EP2726507A1 (de) 2014-05-07
EP3505536B1 (de) 2024-08-07
ES2711978T3 (es) 2019-05-08
EP3505536C0 (de) 2024-08-07
DE102011118022A1 (de) 2013-01-03
AU2012277784A1 (en) 2014-02-06
JP6886491B2 (ja) 2021-06-16
US9200078B2 (en) 2015-12-01
SMT201900085T1 (it) 2019-05-10
PT2726507T (pt) 2019-02-26
US20140134155A1 (en) 2014-05-15
JP2021121201A (ja) 2021-08-26
EP3505536A1 (de) 2019-07-03

Similar Documents

Publication Publication Date Title
EP2726507B1 (de) Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
JP7605912B2 (ja) Gprc5dキメラ抗原受容体及びそれを発現する細胞
EP2480574B1 (de) Anti-cd33 antikörper und ihre anwendung zum immunotargeting bei der behandlung von cd33-assoziierten erkrankungen
DE60127143T2 (de) Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
EP2600889B1 (de) Anti-la antikörper und ihre anwendung zum immunotargeting
US20220144928A1 (en) Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
KR102749049B1 (ko) 분자를 표적화하기 위한 항원 결합 구조체
DE69909459T2 (de) Cd19xcd3 spezifische polypeptide und deren verwendung
US20050176934A1 (en) Antibody combination useful for tumor therapy
JP2024522349A (ja) C-x-cモチーフケモカイン受容体6(cxcr6)結合分子及びその使用方法
DE102010039019B4 (de) Antikörper gegen 6-sulfo LacNAc positive humane dendritische Zellen und deren Verwendung
DE19744531A1 (de) Bindemoleküle gegen Rezeptor-Ligand-Komplexe
HK1197419B (en) Antibodies against prostate-specific stem cell antigen and use thereof
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R123 Application deemed withdrawn due to non-payment of filing fee
R409 Internal rectification of the legal status completed
R409 Internal rectification of the legal status completed
R409 Internal rectification of the legal status completed
R082 Change of representative

Representative=s name: KAILUWEIT & UHLEMANN, PATENTANWAELTE, DE

R081 Change of applicant/patentee

Owner name: GEMOAB MONOCLONALS GMBH, DE

Free format text: FORMER OWNER: TECHNISCHE UNIVERSITAET DRESDEN, 01069 DRESDEN, DE

Effective date: 20140318

R082 Change of representative

Representative=s name: KAILUWEIT & UHLEMANN, PATENTANWAELTE, DE

Effective date: 20140318

Representative=s name: KAILUWEIT & UHLEMANN PATENTANWAELTE PARTNERSCH, DE

Effective date: 20140318

R016 Response to examination communication
R018 Grant decision by examination section/examining division
R020 Patent grant now final
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee